{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:07Z","timestamp":1788437887078,"version":"build-2803163510"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cutaneous melanoma remains a leading cause of skin cancer-related mortality despite significant therapeutic advances, with treatment resistance and immune evasion representing major clinical challenges. Epigenetic dysregulation, particularly through the histone methyltransferases G9a (EHMT2) and Enhancer of Zeste Homolog 2 (EZH2), plays a pivotal role in melanoma progression, therapeutic resistance, and immune escape. G9a catalyzes the deposition of H3K9me2, whereas EZH2, the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), mediates H3K27me3 deposition, thereby establishing repressive chromatin states that silence tumor suppressor genes and immune-related pathways. These enzymes are frequently overexpressed in melanoma and cooperate to maintain dedifferentiated and invasive tumor phenotypes characterized by enhanced plasticity and reduced immunogenicity. Acral melanoma, a distinct subtype with a low ultraviolet (UV) mutational burden, appears to be particularly dependent on epigenetic reprogramming and exhibits an immunologically \u201ccold\u201d tumor microenvironment that is associated with poor responses to current therapies. Preclinical studies demonstrate that pharmacological inhibition of G9a with compounds such as UNC0642 and EZH2 with agents including tazemetostat can restore the expression of silenced genes, enhance antigen presentation, and improve tumor immunogenicity. Importantly, the functional crosstalk between G9a and EZH2 creates redundant repressive mechanisms that may limit the efficacy of single-agent therapies supporting the development of combination strategies targeting both pathways. Dual inhibition has shown promise in pre-clinical models by converting immune-excluded \u201ccold\u201d tumors into immune-responsive \u201chot\u201d tumors that are more susceptible to checkpoint blockade and adoptive cell therapies. While EZH2 inhibitors have progressed to clinical trials in various solid tumors, melanoma-specific studies remain limited despite strong biological rationale. This review synthesizes the current understanding of G9a and EZH2 biology in melanoma, evaluates therapeutic targeting strategies, and highlights the potential for epigenetic reprogramming to overcome treatment resistance and enhance immunotherapy responses in this aggressive malignancy.<\/jats:p>","DOI":"10.3389\/fphar.2026.1879451","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:58:21Z","timestamp":1788436701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular reprogramming in cutaneous melanoma: the central role of G9a and EZH2 methyltransferase inhibitors in tumor plasticity, immune evasion, and therapeutic resistance"],"prefix":"10.3389","volume":"17","author":[{"given":"Melissa Yoshimi Sakamoto Maeda","family":"Nisimoto","sequence":"first","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Arcuschin","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heitor Raia","family":"Bottura","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner Robson","family":"Germano Sousa","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle do Nascimento","family":"Sividanes","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F\u00e1ris","family":"Marques","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaciara Moreira Sodr\u00e9","family":"Hunnicutt","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Giannecchini","family":"Romagnolo","sequence":"additional","affiliation":[{"name":"Experimental Research, Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Clara Ferreira","family":"Vivi","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Linhares","family":"Gorini","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Macedo","family":"Paschoal","sequence":"additional","affiliation":[{"name":"Dermatology Discipline, FMABC University Center","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Sabino","family":"Neto","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Galvonas","family":"Jasiulionis","sequence":"additional","affiliation":[{"name":"Dermatology Discipline, FMABC University Center","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Cavalheiro","family":"Marti","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]},{"name":"Experimental Research, Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Santos","family":"de Oliveira Filho","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo EPM\/UNIFESP)","place":["S\u00e3oPaulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102717","DOI":"10.1016\/j.xcrm.2026.102717","article-title":"Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma","volume":"7","author":"Adan-Villaescusa","year":"2026","journal-title":"Cell Rep. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"873116","DOI":"10.3389\/fimmu.2022.873116","article-title":"Cancer cell phenotype plasticity as a driver of immune escape in melanoma","volume":"13","author":"Benboubker","year":"2022","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.3390\/cancers17172920","article-title":"Melanoma skin cancer: a comprehensive review of current knowledge","volume":"17","author":"Caraviello","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.neo.2023.100947","article-title":"Acral melanoma: new insights into the immune and genomic landscape","volume":"46","author":"Carvalho","year":"2023","journal-title":"Neoplasia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2015.00487","article-title":"Functional role of G9a histone methyltransferase in cancer","volume":"6","author":"Casciello","year":"2015","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1158\/0008-5472.CAN-21-2218","article-title":"Combined inhibition of G9a and EZH2 suppresses tumor growth via synergistic induction of IL24-mediated apoptosis","volume":"82","author":"Casciello","year":"2022","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.molcel.2018.01.039","article-title":"Unique tructural platforms of Suz12 dictate distinct classes of PRC2 for chromatin binding","volume":"69","author":"Chen","year":"2018","journal-title":"Mol. Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-23-3383","article-title":"A phase I\/II study of valemetostat (DS-3201b), an EZH1\/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer","volume":"30","author":"Choudhury","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.18632\/aging.102750","article-title":"Abnormal overexpression of G9a in melanoma cells promotes cancer progression via upregulation of the Notch1 signaling pathway","volume":"12","author":"Dang","year":"2020","journal-title":"Aging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"799636","DOI":"10.3389\/fimmu.2022.799636","article-title":"Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma","volume":"13","author":"De Beck","year":"2022","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/exd.14391","article-title":"Epigenetic regulation during melanocyte development and homeostasis","volume":"30","author":"Dilshat","year":"2021","journal-title":"Exp. Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1016\/j.bioactmat.2021.02.008","article-title":"HIF1\u03b1 epigenetically repressed macrophages via CRISPR\/Cas9-EZH2 system for enhanced cancer immunotherapy","volume":"6","author":"Dong","year":"2021","journal-title":"Bioact. Mater."},{"key":"B17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2767-9764.CRC-23-0399","article-title":"EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas","volume":"4","author":"DuCote","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy","volume":"40","author":"Emran","year":"2019","journal-title":"Trends Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e27085","DOI":"10.1016\/j.heliyon.2024.e27085","article-title":"Molecular and functional anticancer effects of GLP\/G9a inhibition by UNC0646 in MeWo melanoma cells","volume":"10","author":"Fili\u00fa-Braga","year":"2024","journal-title":"Heliyon"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/mc.22448","article-title":"The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane","volume":"55","author":"Fisher","year":"2016","journal-title":"Mol. Carcinog."},{"key":"B21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/epigenomes5040023","article-title":"G9a: an emerging epigenetic target for melanoma therapy","volume":"5","author":"Flesher","year":"2021","journal-title":"Epigenomes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/cells10082048","article-title":"Epigenetic regulation in melanoma: facts and hopes","volume":"10","author":"Giunta","year":"2021","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","article-title":"Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy","volume":"128","author":"Goswami","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0242191","DOI":"10.1371\/journal.pone.0242191","article-title":"EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma","volume":"15","author":"Guo","year":"2020","journal-title":"PLoS ONE"},{"key":"B25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/cells9010142","article-title":"Dissecting mechanisms of melanoma resistance to BRAF and MEK inhibitors revealed genetic and non-genetic patient- and drug-specific alterations and remarkable phenotypic plasticity","volume":"9","author":"Hartman","year":"2020","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1728091","DOI":"10.3389\/fimmu.2025.1728091","article-title":"Epigenetic control of antigen presentation failure in osteosarcoma: from single-cell chromatin maps to therapeutic strategies","volume":"16","author":"He","year":"2025","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1021\/acs.jmedchem.4c02781","article-title":"Current and emerging approaches targeting G9a for the treatment of various diseases","volume":"68","author":"He","year":"2025","journal-title":"J. Med. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-020-0818-7","article-title":"H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade","volume":"12","author":"Hoffmann","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2326-6066.CIR-24-0089","article-title":"Transient EZH2 suppression by tazemetostat during in vitro expansion maintains T-cell stemness and improves adoptive T-cell therapy","volume":"13","author":"Hou","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"756001","DOI":"10.3389\/fonc.2021.756001","article-title":"Melanoma plasticity: promoter of metastasis and resistance to therapy","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell Non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"TPS1120","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1120","article-title":"Phase 1b study of EZH1\/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low\/ultra-low\/null metastatic breast cancer","volume":"42","author":"Iwase","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e007736","DOI":"10.1136\/jitc-2023-007736","article-title":"Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance","volume":"11","author":"James","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"173827","DOI":"10.1016\/j.ejphar.2020.173827","article-title":"Targeting EHMT2\/G9a for cancer therapy: progress and perspective","volume":"893","author":"Jan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"127475","DOI":"10.1016\/j.bmcl.2020.127475","article-title":"Discovery of novel histone lysine methyltransferase G9a\/GLP (EHMT2\/1) inhibitors: design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines","volume":"30","author":"Katayama","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/cas.15681","article-title":"The cancer epigenome: non-cell autonomous player in tumor immunity","volume":"114","author":"Kato","year":"2023","journal-title":"Cancer Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/2159-8290.CD-23-0110","article-title":"Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy","volume":"14","author":"Kazansky","year":"2024","journal-title":"Cancer Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1158\/1078-0432.CCR-20-3463","article-title":"G9a inhibition enhances checkpoint inhibitor blockade response in melanoma","volume":"27","author":"Kelly","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/biom15010120","article-title":"Acral melanoma: a review of its pathogenesis, progression, and management","volume":"15","author":"Kim","year":"2025","journal-title":"Biomolecules"},{"key":"B42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.molcel.2017.01.009","article-title":"Polycomb repressive complex 1 generates discrete compacted domains that change during differentiation","volume":"65","author":"Kundu","year":"2017","journal-title":"Mol. Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41467-024-46422-5","article-title":"Mi-2\u03b2 promotes immune evasion in melanoma by activating EZH2 methylation","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1308264","DOI":"10.3389\/fimmu.2023.1308264","article-title":"Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"102452","DOI":"10.1016\/j.tranon.2025.102452","article-title":"Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma","volume":"59","author":"Liguori","year":"2025","journal-title":"Transl. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1021\/jm401480r","article-title":"Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP","volume":"56","author":"Liu","year":"2013","journal-title":"J. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1172\/JCI130038","article-title":"H3K27me3-mediated PGC1\u03b1 gene silencing promotes melanoma invasion through WNT5A and YAP","volume":"130","author":"Luo","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"eadk8832","DOI":"10.1126\/scitranslmed.adk8832","article-title":"Single-cell profiling of acral melanoma infiltrating lymphocytes reveals a suppressive tumor microenvironment","volume":"16","author":"Minowa","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.molcel.2013.12.005","article-title":"The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing","volume":"53","author":"Mozzetta","year":"2014","journal-title":"Mol. Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.3390\/cancers16122175","article-title":"G9a in cancer: mechanisms, therapeutic advancements, and clinical implications","volume":"16","author":"Ni","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1182\/bloodadvances.2023010571","article-title":"Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma","volume":"9","author":"Nylund","year":"2025","journal-title":"Blood Adv."},{"key":"B54","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/cancers17030437","article-title":"Tazemetostat, a selective EZH2 inhibitor, in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a phase 1 trial","volume":"17","author":"Oppelt","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/biomedicines11010169","article-title":"Targeting epigenetic mechanisms: a boon for cancer immunotherapy","volume":"11","author":"Parab","year":"2023","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1038\/s41388-019-0729-2","article-title":"An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells","volume":"38","author":"Perotti","year":"2019","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41698-025-00826-8","article-title":"Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat","volume":"9","author":"Resch","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1479-5876-8-56","article-title":"Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies","volume":"8","author":"Sigalotti","year":"2010","journal-title":"J. Transl. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12935-024-03441-y","article-title":"GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms","volume":"24","author":"Silva-Carvalho","year":"2024","journal-title":"Cancer Cell Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1096615","DOI":"10.3389\/fmed.2023.1096615","article-title":"SWI\/SNF complex, promising target in melanoma therapy: snapshot view","volume":"10","author":"Sisakht","year":"2023","journal-title":"Front. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/febs.16395","article-title":"Cancer epigenetics: promises and pitfalls for cancer therapy","volume":"289","author":"Skourti","year":"2022","journal-title":"FEBS J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1101\/gad.1284005","article-title":"Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9","volume":"19","author":"Tachibana","year":"2005","journal-title":"Genes Dev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cpdd.1315","article-title":"Safety, tolerability, and pharmacokinetics of valemetostat tablets and the effect of food on valemetostat pharmacokinetics in healthy subjects: two phase 1 studies","volume":"13","author":"Tachibana","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1986350","DOI":"10.1080\/23723556.2021.1986350","article-title":"Chromatin state profiling reveals PRC2 inhibition as a therapeutic target in NRAS-mutant melanoma","volume":"8","author":"Terranova","year":"2021","journal-title":"Mol. Cell. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akdemir","year":"2015","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/pcmr.12280","article-title":"EZH2: an emerging role in melanoma biology and strategies for targeted therapy","volume":"28","author":"Tiffen","year":"2015","journal-title":"Pigment. Cell Melanoma Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/pcmr.12481","article-title":"EZH2 as a mediator of treatment resistance in melanoma","volume":"29","author":"Tiffen","year":"2016","journal-title":"Pigment. Cell Melanoma Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/biomedicines13051188","article-title":"Epigenetic therapies in melanoma-targeting DNA methylation and histone modification","volume":"13","author":"Tigu","year":"2025","journal-title":"Biomedicines"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/ijms24031963","article-title":"Resistance to BRAF inhibitors: EZH2 and its downstream targets as potential therapeutic options in melanoma","volume":"24","author":"Uebel","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3390\/cancers17193111","article-title":"EZH2 dysregulation and its oncogenic role in human cancers","volume":"17","author":"Verma","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.trecan.2025.11.010","article-title":"Epigenetic drivers of chromosomal instability","volume":"12","author":"Vitale","year":"2026","journal-title":"Trends Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.acr.2022.12.001","article-title":"Epigenetically programmed resistance to chemo- and immuno-therapies","volume":"158","author":"Walker","year":"2023","journal-title":"Adv. Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e70027","DOI":"10.1111\/pcmr.70027","article-title":"Comprehensive profiling of acral lentiginous melanoma reveals downregulated immune activation compared to cutaneous melanoma","volume":"38","author":"Wang","year":"2025","journal-title":"Pigment. Cell Melanoma Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jid.2021.08.437","article-title":"EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma","volume":"142","author":"Xu","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1093\/neuonc\/noae064.168","article-title":"TRLS-15. \u201cTAZNI\u201d: a phase I\/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors (NCT05407441)","volume":"26","author":"Yi","year":"2024","journal-title":"Neuro Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10555-020-09944-0","article-title":"Epigenetic modulation of immunotherapy and implications in head and neck cancer","volume":"40","author":"Zhou","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"B80","doi-asserted-by":"publisher","first-page":"101223","DOI":"10.1016\/j.neo.2025.101223","article-title":"A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAFV600E inhibition in melanoma","volume":"68","author":"Zhou","year":"2025","journal-title":"Neoplasia"},{"key":"B81","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat. Commun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1879451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:58:22Z","timestamp":1788436702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1879451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":82,"alternative-id":["10.3389\/fphar.2026.1879451"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1879451","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1879451"}}